Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?
Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!
What Cellectar Biosciences, Inc.’s CLOVER WaM data reveals about fixed-duration oncology therapies
Can iopofosine I 131 reshape Waldenström macroglobulinemia treatment? Explore durability data and regulatory outlook driving momentum.
TScan Therapeutics strengthens heme pipeline with dual IND clearances
TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.
Is deceased donor marrow a viable backup graft? First human data from Ossium says yes
Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.